HPMA-copolymer conjugates targeted to tumor endothelium using synthetic oligopeptides

References

• Aina OH, Sroka TC, Chen ML, Lam KS. (2002). Therapeutic cancer targeting peptides. Biopolymers, 66(3), 184–199.
   PubMed Web of Science ®Google Scholar
• Alessi P, Ebbinghaus C, Neri D. (2004). Molecular targeting of angiogenesis. BBA-Rev Cancer, 1654(1), 39–49.
   PubMed Web of Science ®Google Scholar
• Arap W, Pasqualini R, Ruoslahti E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279(5349), 377–380.
   PubMed Web of Science ®Google Scholar
• Avichezer D, Schechter B, Arnon R. (1998). Functional polymers in drug delivery: carrier-supported CDDP (cis-platin) complexes of polycarboxylates—effect on human ovarian carcinoma. React Funct Polym, 36(1), 59–69.
   Web of Science ®Google Scholar
• Bauer J, Margolis M, Schreiner C, Edgell CJ, Azizkhan J, Lazarowski E, Juliano RL. (1992). In vitro model of angiogenesis using a human endothelium-derived permanent cell-line— contributions of induced gene-expression, G-proteins, and integrins. J Cell Physiol, 153(3), 437–449.
   PubMed Web of Science ®Google Scholar
• Beer JH, Springer KT, Coller BS. (1992). Immobilized Arg-Gly-Asp (Rgd) peptides of varying lengths as structural probes of the platelet glycoprotein-Iib/Iiia receptor. Blood, 79(1), 117–128.
   PubMed Web of Science ®Google Scholar
• Borgman MP, Coleman T, Kolhatkar RB, Geyser-Stoops S, Line BR, Ghandehari H. (2008). Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A’’-DTPA) conjugates show increased kidney accumulation. J Control Release, 132(3), 193–199.
   PubMed Web of Science ®Google Scholar
• Brekken RA, Thorpe PE. (2001). Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res, 21(6B), 4221–4229.
   PubMed Web of Science ®Google Scholar
• Brooks PC, Clark RAF, Cheresh DA. (1994). Requirement of vascular integrin alpha(V)beta(3) for angiogenesis. Science, 264(5158), 569–571.
   PubMed Web of Science ®Google Scholar
• Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE. (1995). Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res, 1(12), 1623–1634.
   PubMed Web of Science ®Google Scholar
• Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB. (1999). Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res, 5(10), 2674–2681.
   PubMed Web of Science ®Google Scholar
• Chari RVJ. (1998). Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev, 31(1–2), 89–104.
   PubMed Web of Science ®Google Scholar
• Delbuono R, Pignatelli M, Bodmer WF, Wright NA. (1991). The role of the arginine-glycine-aspartic acid-directed cellular-binding to type-I collagen and rat mesenchymal cells in colorectal tumor differentiation. Differentiation, 46(2), 97–103.
   PubMed Web of Science ®Google Scholar
• Duncan R. (2006). Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer, 6(9), 688–701.
   PubMed Web of Science ®Google Scholar
• Dunehoo AL, Anderson M, Majumdar S, Kobayashi N, Berkland C, Siahaan TJ. (2006). Cell adhesion molecules for targeted drug delivery. J Pharm Sci, 95(9), 1856–1872.
   PubMed Web of Science ®Google Scholar
• Feng YZ, Mrksich M. (2004). The synergy peptide PHSRN and the adhesion peptide RGD mediate cell adhesion through a common mechanism. Biochemistry, 43(50), 15811–15821.
   PubMed Web of Science ®Google Scholar
• Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. (1996). Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alpha(v)beta(3) antagonists. J Am Chem Soc, 118(32), 7461–7472.
   Web of Science ®Google Scholar
• Hoste K, De Winne K, Schacht E. (2004). Polymeric prodrugs. Int J Pharm, 277(1–2), 119–131.
   PubMedGoogle Scholar
• Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesslewood S, Kerr DJ. (1999). Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J Control Release, 57(3), 281–290.
   PubMed Web of Science ®Google Scholar
• Kaiser E, Colescot RL, Bossinge CD, Cook PI. (1970). Color test for detection of free terminal amino groups in solid-phase synthesis of peptides. Anal Biochem, 34(2), 595–598.
   PubMed Web of Science ®Google Scholar
• Kissel M, Peschke P, Šubr V, Ulbrich K, Schuhmacher J, Debus J, Friedrich E. (2001). Synthetic macromolecular drug carriers: biodistribution of poly[(N-2-hydroxypropyl)methacrylamide] copolymers and their accumulation in solid rat tumors. J Pharm Sci Technol, 55(3), 191–201.
   Google Scholar
• Kopeček J, Kopečková P, Minko T, Lu ZR. (2000). HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm, 50(1), 61–81.
   PubMed Web of Science ®Google Scholar
• Kovář L, Strohalm J, Chytil P, Mrkvan T, Kovář M, Hovorka O, Ulbrich K, Říhová B. (2007). The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line. Bioconjug Chem, 18(3), 894–902.
   PubMed Web of Science ®Google Scholar
• Leyton L, Schneider P, Labra CV, Ruegg C, Hetz CA, Quest AFG, Bron C. (2001). Thy-1 binds to integrin beta(3) on astrocytes and triggers formation of focal contact sites. Curr Biol, 11(13), 1028–1038.
   PubMed Web of Science ®Google Scholar
• Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, Upadhyaya A. (2000). Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res, 60(2), 309–320.
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65(1–2), 271–284.
   PubMed Web of Science ®Google Scholar
• Minko T, Kopečková P, Pozharov V, Kopeček J. (1998). HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release, 54(2), 223–233.
   PubMed Web of Science ®Google Scholar
• Mitra A, Coleman T, Borgman M, Nan A, Ghandehari H, Line BR. (2006). Polymeric conjugates of mono- and bi-cyclic alpha(V)beta(3) binding peptides for tumor targeting. J Control Release, 114(2), 175–183.
   PubMed Web of Science ®Google Scholar
• Monfardini C, Veronese FM. (1998). Stabilization of substances in circulation. Bioconjug Chem, 9(4), 418–450.
   PubMed Web of Science ®Google Scholar
• Mori T. (2004). Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des, 10(19), 2335–2343.
   PubMed Web of Science ®Google Scholar
• Nilsson F, Kosmehl H, Zardi L, Neri D. (2001). Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res, 61(2), 711–716.
   PubMed Web of Science ®Google Scholar
• Pasqualini R, Koivunen E, Ruoslahti E. (1997). Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol, 15(6), 542–546.
   PubMed Web of Science ®Google Scholar
• Roberts MS, Woods AJ, Shaw PE, Norman JC. (2003). ERK1 associates with alpha(v)beta 3 integrin and regulates cell spreading on vitronectin. J Biol Chem, 278(3), 1975–1985.
   PubMed Web of Science ®Google Scholar
• Ruegg C, Dormond O, Foletti A. (2002). Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium NY, 9(3), 151–160.
   Google Scholar
• Říhová B. (2003). Anti body-targeted HPMA copolymer-bound anthracycline antibiotics. Drugs Future, 28(12), 1189–1210.
   Web of Science ®Google Scholar
• Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G, Folkman J. (2004). Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med, 10(3), 255–261.
   PubMed Web of Science ®Google Scholar
• Satchi-Fainaro R, Duncan R, Barnes CM. (2006). Polymer therapeutics for cancer: current status and future challenges. Adv Polym Sci, 193, 1–65.
   Web of Science ®Google Scholar
• Sauer LA, Dauchy RT. (1992). The effect of omega-6 and omega-3-fatty-acids on H-3 thymidine incorporation in hepatoma- 7288Ctc perfused in situ. Br J Cancer, 66(2), 297–303.
   PubMed Web of Science ®Google Scholar
• Seon BK. (2002). Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer, 99(2), 310–311.
   PubMed Web of Science ®Google Scholar
• Seymour LW, Duncan R, Strohalm J, Kopeček J. (1987). Effect of molecular-weight (Mbarw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res, 21(11), 1341–1358.
   PubMed Web of Science ®Google Scholar
• Shadidi M, Sioud M. (2003). Selective targeting of cancer cells using synthetic peptides. Drug Resist Update, 6(6), 363–371.
   PubMed Web of Science ®Google Scholar
• Sieber P. (1987). A new acid-labile anchor group for the solid-phase synthesis of c-terminal peptide amides by the fmoc method. Tetrahedron Lett, 28(19), 2107–2110.
   Web of Science ®Google Scholar
• Šubr V, Strohalm J, Hirano T, Ito Y, Ulbrich K. (1997). Poly[N-(2-hydroxypropyl)methacrylamide] conjugates of methotrexate—synthesis and in vitro drug release. J Control Release, 49(2-3), 123–132.
   Web of Science ®Google Scholar
• Ulbrich K, Šubr V, Strohalm J, Plocová D, Jelínková M, Říhová B. (2000). Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation. J Control Release, 64(1–3), 63–79.
   PubMed Web of Science ®Google Scholar
• Veenendaal LM, Jin HQ, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG. (2002). In vitro and in vivo studies of a VEGF(121)/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA, 99(12), 7866–7871.
   PubMed Web of Science ®Google Scholar
• Větvička D, Baumgartnerová E, Hovorka O, Kovář L, Říhová B. (2009). Establishment of imageable mouse model of T-cell lymphoma growing in syngenic mice. Anticancer Res (in press).
   Google Scholar
• Yamamoto Y, Tsutsumi Y, Mayumi T. (2002). Molecular design of bioconjugated cell adhesion peptide with a water-soluble polymeric modifier for enhancement of antimetastatic effect. Curr Drug Targets, 3(2), 123–130.
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Yang M, Jiang P, Xu MX, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM. (2006). Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res, 66(8), 4208–4214.
   PubMed Web of Science ®Google Scholar
• Young SL, Chaplin DJ. (2004). Combretastatin A4 phosphate: background and current clinical status. Expert Opin Invest Drugs, 13(9), 1171–1182.
   PubMed Web of Science ®Google Scholar